Get started
Edgewise Therapeutics, Inc.Edgewise Therapeutics, Inc.Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

EWTX chart


Full chart

EWTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.98 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.49 USD
Net income (FY)
‪−100.16 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪62.41 M‬
Beta (1Y)
2.92

Employees


Employees (FY)
88
Change (1Y)
+29 +49.15%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.14 M‬ USD

About Edgewise Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Kevin Koch
Website
edgewisetx.com
Headquarters
Boulder
Founded
2017
FIGI
BBG00K4Y2H24
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

EWTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of EWTX is 31.95 USD — it has increased by 2.34% in the past 24 hours. Watch Edgewise Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Edgewise Therapeutics, Inc. stocks are traded under the ticker EWTX.
EWTX stock has fallen by −10.58% compared to the previous week, the month change is a −10.15% fall, over the last year Edgewise Therapeutics, Inc. has showed a 403.15% increase.
We've gathered analysts' opinions on Edgewise Therapeutics, Inc. future price: according to them, EWTX price has a max estimate of 51.00 USD and a min estimate of 33.00 USD. Watch EWTX chart and read a more detailed Edgewise Therapeutics, Inc. stock forecast: see what analysts think of Edgewise Therapeutics, Inc. and suggest that you do with its stocks.
EWTX reached its all-time high on Mar 29, 2021 with the price of 40.49 USD, and its all-time low was 5.12 USD and was reached on Nov 10, 2023. View more price dynamics on EWTX chart.
See other stocks reaching their highest and lowest prices.
EWTX stock is 3.27% volatile and has beta coefficient of 2.92. Track Edgewise Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Edgewise Therapeutics, Inc. there?
Today Edgewise Therapeutics, Inc. has the market capitalization of ‪2.98 B‬, it has decreased by −3.88% over the last week.
Yes, you can track Edgewise Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Edgewise Therapeutics, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
EWTX earnings for the last quarter are −0.36 USD per share, whereas the estimation was −0.37 USD resulting in a 3.19% surprise. The estimated earnings for the next quarter are −0.40 USD per share. See more details about Edgewise Therapeutics, Inc. earnings.
Edgewise Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
EWTX net income for the last quarter is ‪−34.13 M‬ USD, while the quarter before that showed ‪−31.50 M‬ USD of net income which accounts for −8.36% change. Track more Edgewise Therapeutics, Inc. financial stats to get the full picture.
No, EWTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 88.00 employees. See our rating of the largest employees — is Edgewise Therapeutics, Inc. on this list?
Like other stocks, EWTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Edgewise Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Edgewise Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Edgewise Therapeutics, Inc. stock shows the buy signal. See more of Edgewise Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.